Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SLC6A15 | Q9H2J7 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294501 | 0.85 | ESR2 (0.45) | MAPTMAPK1MEN1KMT2AHTT | |
| SCHEMBL1294286 | 0.78 | ALDH1A1 (0.44) | MAPTLMNACYP2C9ALOX15CYP2C19 | |
| SCHEMBL1293437 | 0.75 | ESR2 (0.43) | MAPTMAPK1 | |
| SCHEMBL1294161 | 0.73 | LMNA (0.42) | MAPTLMNAMAPK1CYP3A4MEN1 | |
| SCHEMBL15828470 | 0.71 | MAPT (0.46) | MAPTSLC6A15HRH1LMNAMAPK1 | |
| SCHEMBL1294353 | 0.71 | MAPT (0.43) | MAPTLMNAMAPK1CYP3A4ALOX15 | |
| SCHEMBL12106939 | 0.70 | MAPT (0.46) | MAPTSLC6A15LMNAMAPK1CYP3A4 | |
| SCHEMBL1294850 | 0.70 | ESR2 (0.45) | MAPTMAPK1MEN1NPC1RAB9A | |
| SCHEMBL1294543 | 0.69 | HTR2C (0.44) | HTR2AHTR2B | |
| SCHEMBL15869771 | 0.69 | ALDH1A1 (0.45) | MAPTLMNAMAPK1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598434-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2017-03-21 | — | — | US | disclosed |
| EP-2546255-B1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9108977-B2 | Benzazepine compound | ASTELLAS PHARMA INC. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-03-07 | — | — | US | disclosed |
| EP-2546255-A1 | BENZAZEPINE COMPOUND | Astellas Pharma Inc. (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012496-A1 | BENZAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012496-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | MAPT 3913/4885SLC6A15 651/4885HRH1 550/4885 |
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | MAPT 3580/4885SLC6A15 805/4885HRH1 398/4885 |
| US-20130059837-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | MAPT 3913/4885SLC6A15 651/4885HRH1 550/4885 |
| US-20150315208-A1 | BENZAZEPINE COMPOUND | HTR2C, HTR2A, HTR3C | MAPT 3913/4885SLC6A15 651/4885HRH1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.